- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01848691
Carbon Monoxide Monitor for the Measurement of End-Tidal Carbon Monoxide Levels in Children With or Without Hemolysis
May 29, 2014 updated by: Ashutosh Lal
Phase 1 Study of Carbon Monoxide Monitor for the Measurement of End-Tidal Carbon Monoxide Levels in Children With or Without Hemolysis
People who have Sickle Cell Anemia (HbSS) produce red blood cells with shorter lifespans.
These red blood cells breakdown faster, and this is called hemolysis.
When red blood cells breakdown, a tiny amount of Carbon Monoxide (CO) is released into the blood and is eliminated in exhaled breath.
This research study will use a device called CoSense™, which will measure Carbon Monoxide (CO) levels in breath.
The purpose of the study is to see how well the device measures the CO levels that an individual breathes out.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
Subjects diagnosed with homozygous sickle cell anemia (Hb SS) have red blood cells with a decreased lifespan, which leads to an increase in the rate of heme turnover.
Carbon monoxide (CO) is a by-product of heme oxidation and is excreted in exhaled breath.
The concentration of CO in end-tidal breath can be measured and used to indicate the rate of heme oxidation, bilirubin production and the presence of hemolysis.
The objective of this study is to characterize the performance of CoSense™ in children with or without sickle cell anemia.
This is a single-center, open-label, non-randomized, proof of concept study to characterize the ability of CoSense™ to assess ETCO levels in subjects with a diagnosis of sickle cell anemia (Hb SS).
Up to 40 children (5-14 years old), of which 20 participants will have a diagnosis of Hb SS, will be enrolled.
Each participant will have two breath samples collected non-invasively, one immediately after the other.
It takes approximately 120 seconds to collect the each breath sample.
This study and investigational device are a non-significant risk to the patient.
The nasal cannula is made of a biocompatibility-tested polyvinyl chloride (PVC) material with a soft open-end, and will be gently placed adjacent to one of the nostrils and partially inserted by approximately 5 mm.
The objective of this study will be assessed through reproducibility of ETCO measurements and comparison of ETCO levels between children diagnosed with Hb SS and healthy children.
The study would help in the development of a portable CO measurement device which has potential health applications in monitoring diseases with altered bilirubin metabolism.
Study Type
Interventional
Enrollment (Actual)
40
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
California
-
Oakland, California, United States, 94609
- Children's Hospital & Research Center Oakland
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
5 years to 14 years (Child)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Parental / legal guardian consent
- Subject assent for participants ages 7 and above
- Male and female children ages 5 - 14 years old
- For Hb SS subjects, hemoglobin ≤ 10 g/dL (based on a laboratory tests performed over the last 6 months and confirmed within 4 weeks prior to breath collection, as part of the subject's clinical care)
Exclusion Criteria:
- For healthy subjects, known to have the sickle cell trait
- Had a red blood cell transfusion within 12 weeks prior to enrollment
- Currently a primary smoker or was a primary smoker within 4 weeks prior to enrollment
- Exposed to second hand smoke within 24 hours prior to breath sample collections
- Have an upper respiratory infection within 2 weeks of ETCO measurements
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Diagnostic
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Sickle Cell
This arm will include 20 children with sickle cell anemia
|
Measurement of end-tidal carbon monoxide concentration
Other Names:
|
Active Comparator: Control
This arm will include 20 children without sickle cell anemia
|
Measurement of end-tidal carbon monoxide concentration
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
End-Tidal Carbon Monoxide Concentration
Time Frame: one year
|
one year
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Ashutosh Lal, MD, Children'S Hospital & Research Center At Oakland
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
October 1, 2012
Primary Completion (Actual)
March 1, 2014
Study Completion (Actual)
March 1, 2014
Study Registration Dates
First Submitted
May 3, 2013
First Submitted That Met QC Criteria
May 3, 2013
First Posted (Estimate)
May 7, 2013
Study Record Updates
Last Update Posted (Estimate)
June 2, 2014
Last Update Submitted That Met QC Criteria
May 29, 2014
Last Verified
May 1, 2014
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Pathologic Processes
- Hematologic Diseases
- Genetic Diseases, Inborn
- Anemia
- Anemia, Hemolytic, Congenital
- Anemia, Hemolytic
- Hemoglobinopathies
- Anemia, Sickle Cell
- Hemolysis
- Physiological Effects of Drugs
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Antimetabolites
- Gasotransmitters
- Carbon Monoxide
Other Study ID Numbers
- Capnia CoSense Award 12.8062
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
product manufactured in and exported from the U.S.
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Sickle Cell Anemia
-
Klein Buendel, Inc.National Institute on Minority Health and Health Disparities (NIMHD); Hilton...CompletedSickle Cell Disease | Sickle Cell Anemia in Children | Sickle Cell Thalassemia | Sickle Cell SC DiseaseUnited States
-
National Heart, Lung, and Blood Institute (NHLBI)Enrolling by invitationSickle Cell Anemia | Sickle Beta Thalassemia | Sickle Cell Thalassemia | Sickle Beta Zero Thalassemia | Sickle Cell Pain | Hbss | Hbsc | Sickle Cell Syndrome VariantUnited States
-
Brown UniversityNational Heart, Lung, and Blood Institute (NHLBI); NovartisRecruitingSickle Cell Disease | Sickle Cell Anemia in ChildrenAngola
-
SangartCompletedSickle Cell Disease | Anemia, Sickle Cell | Sickle Cell Anemia | Hemoglobin SC Disease | Sickle Cell Disorders | Sickle Cell Hemoglobin C DiseaseUnited Kingdom, France, Jamaica, Lebanon
-
University of British ColumbiaCompletedSickle Cell Disease | Beta-Thalassemia | Sickle Cell Trait | Sickle Cell-Beta Thalassemia | Sickle Cell-SS DiseaseCanada, Nepal
-
SangartWithdrawnSickle Cell Disease | Anemia, Sickle Cell | Sickle Cell Anemia | Hemoglobin SC Disease | Sickle Cell Disorders | Sickle Cell Hemoglobin C DiseaseFrance, United Kingdom, Netherlands, Turkey, Bahrain, Belgium, Brazil, Lebanon, Qatar
-
Beni-Suef UniversityUniversity of Arizona; Maternity and Children Hospital, Makkah; Benisuef university...CompletedSickle Cell Disease | Vaso-occlusive Crisis | Sickle Cell Anemia in ChildrenEgypt, Saudi Arabia
-
National Institute of Diabetes and Digestive and...RecruitingSickle Cell Disease | Sickle Cell Anemia | Sickle Cell TraitUnited States
-
Sidney Kimmel Cancer Center at Thomas Jefferson...National Heart, Lung, and Blood Institute (NHLBI)TerminatedSickle Cell Anemia | Sickle Cell-hemoglobin C Disease | Sickle Cell-β0-thalassemiaUnited States
-
Amy TangPfizerRecruitingSickle Cell Anemia in ChildrenUnited States
Clinical Trials on Measurement of carbon monoxide level in exhaled breath
-
University of AthensRecruitingConcentration of Exhaled Carbon MonoxideGreece
-
University of CincinnatiVA Office of Research and DevelopmentUnknown
-
Jennifer Marler, MDUserWise, LLCCompleted
-
Milton S. Hershey Medical CenterCompleted
-
Centre Hospitalier Universitaire de Saint EtienneAide à la Recherche Médicale Ondaine et EnvironsTerminatedChronic Obstructive Pulmonary DiseaseFrance
-
David Utley, MDUserWise, LLCCompletedSmoking, TobaccoUnited States
-
Assistance Publique - Hôpitaux de ParisFondation Cœur et RechercheActive, not recruitingSubstance-Related Disorders | Drug Abuse | Cardiac Disease | Intensive Care Unit Syndrome | Cardiovascular EventsFrance
-
University Children's Hospital BaselSwiss National Science Foundation; Fondation BotnarCompletedDe Novo Lipogenesis (DNL)Switzerland
-
University of FloridaUniversity of OklahomaCompleted
-
Duke UniversityCase Western Reserve UniversityRecruiting